Concord Biotech Share News - Latest Updates, Live News & More

Latest news about Concord Biotech

Concord Biotech Reports 14% Revenue Growth in Q3 FY26, Injectable Facility Gets WHO GMP Certification 3 hrs ago Today

Concord Biotech Limited reported Q3 FY26 revenues of ₹278 crores, marking 14% year-on-year growth, with API business driving performance through 24% growth to ₹219 crores. The company's injectable facility received WHO GMP certification with ₹600 crores peak revenue potential, while nine-month revenues declined 5% due to first-half challenges including U.S. tariff uncertainties and regulatory delays. EBITDA margins stood at 35.60%, impacted by injectable facility commercialization costs, with management expressing optimism for Q4 performance and normalized growth returning in FY27.

Concord Biotech Publishes Q3FY26 Financial Results in Newspapers 7 days ago

Concord Biotech Limited Announces Resignation of Company Secretary and Compliance Officer Dec 24, 2025

Concord Biotech Appoints Raviraj Karia as New CFO, Effective December 18, 2025 Dec 08, 2025

Concord Biotech Reports Q2 FY26 Revenue Decline Amid Regulatory Delays and Market Disruptions Nov 19, 2025

More news about Concord Biotech

15Nov 25

Concord Biotech Anticipates Robust Growth in H2 FY26, Eyes 25% CAGR

Concord Biotech anticipates stronger performance in H2 FY26 compared to H2 FY25, with better clarity expected by Q4. The company's injectable facility could potentially generate INR 400-600 crores in revenue, targeting a total addressable market of INR 3,000-4,000 crores. Management believes the company has the capability to achieve a 25% CAGR, driven by existing facilities, product mix, and new revenue-generating facilities. The company recently made its Q2 FY26 earnings call recording available.

14Nov 25

Concord Biotech Q2 Profit Drops 34% to ₹63.6 Crore; Board Approves Strategic Acquisitions

Concord Biotech, a biopharma company specializing in fermentation-based APIs, reported a 20.4% YoY revenue decline to ₹247.10 crore and a 33.6% drop in net profit to ₹63.60 crore in Q2 FY26. The decline was attributed to regulatory delays, U.S. order holds, and Middle East contract deferments. Despite challenges, the company expanded gross margins by 480 bps YoY and secured multiple regulatory approvals. Strategic decisions include acquiring Celliimune Biotech and investing in a solar power project. The company remains optimistic about future growth, citing advanced discussions with innovator companies and plans for geographic expansion.

08Oct 25

Concord Biotech Successfully Completes NAFDAC Inspection at Valthera Facility

Concord Biotech's Oral Solid Dosage (OSD) Unit-2 facility in Valthera, Gujarat, successfully completed a regulatory inspection by Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) on October 6-7, 2025. This achievement demonstrates the company's commitment to quality assurance, regulatory compliance, and operational excellence, potentially facilitating access to the Nigerian pharmaceutical market.

21Aug 25

Concord Biotech Completes EU GMP Inspection at Limbassi API Facility

Concord Biotech Limited has successfully completed a European Union Good Manufacturing Practice (EU GMP) inspection at its Active Pharmaceutical Ingredient (API) facility in Limbassi. The inspection, conducted from August 18 to August 21, 2025, was the first EU GMP inspection at this site. This achievement is expected to enhance the company's global footprint, enable expansion into EU markets, and strengthen its regulatory compliance. Concord Biotech views this as a validation of their commitment to quality standards and operational excellence.

18Aug 25

Concord Biotech Reports Q1 Results: Revenue Dips 5% Amid Customer Procurement Lumpiness

Concord Biotech Limited reported Q1 FY26 results with revenue at ₹204 crores, down 5% YoY. EBITDA decreased 24.7% to ₹61 crores, with margins contracting to 30.1%. PAT fell 26.7% to ₹44 crores. API business revenue declined 10%, while formulation business grew 12%. The company received US FDA approval for teriflunomide tablets and passed various regulatory inspections. Management attributed the performance to revenue lumpiness and initial costs from the new injectable facility. Despite short-term challenges, the company remains optimistic about long-term growth prospects.

13Aug 25

Concord Biotech Reports Q1FY26 Results: Revenue Down 5%, EBITDA Declines 24%

Concord Biotech's Q1FY26 results show a 5% decrease in revenue to Rs 204.00 crores, with EBITDA falling 24% to Rs 61.00 crores. PAT declined 26% to Rs 44.00 crores. Despite financial challenges, the company made operational progress, including commencing CDMO services, passing regulatory inspections, acquiring a stake in Stellon Biotech, and incorporating a new subsidiary for domestic operations. The company maintains an optimistic outlook for FY26 growth.

12Aug 25

Concord Biotech Targets 25% Annual Growth, Releases Q1 FY26 Earnings Call Recording

Concord Biotech Limited aims for 25% annual growth, building on its historical 18% growth rate. The company expects an additional 6-7% growth from CDMO operations, valued at $40-50 million, and 5% from its injectable facility. While specific FY26 guidance wasn't provided, the company anticipates performance in line with historical trends. Concord Biotech has made its Q1 FY26 earnings call audio, discussing results for the quarter ended June 30, 2025, publicly available.

10Aug 25

Concord Biotech Reports Mixed Q1 Results with 5% Revenue Decline, Expands US Operations

Concord Biotech reported a 5% YoY revenue decline to Rs 204.00 crores in Q1, with EBITDA and PAT falling 24% and 26% respectively. Despite this, the company achieved key operational milestones including successful regulatory inspections, commencement of CDMO supplies to a US customer, acquisition of a 75% stake in US-based Stellon Biotech, and incorporation of a wholly-owned subsidiary for domestic marketing. Management remains optimistic about future growth prospects driven by geographical expansion, new product launches, and increased CDMO opportunities.

26Jul 25

Concord Biotech Successfully Completes Russian GMP Inspection at Gujarat API Facility

Concord Biotech Limited successfully completed a Russian Good Manufacturing Practice (GMP) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Dholka, Gujarat. The inspection, conducted from July 22 to July 25, 2025, evaluated the company's manufacturing processes and facilities. This achievement demonstrates Concord Biotech's commitment to maintaining high standards of quality, safety, and regulatory compliance. The successful inspection could potentially open new opportunities for the company in the Russian pharmaceutical market and reinforces its position as a reliable API manufacturer.

22Jul 25

Concord Biotech Expands Operations with New Subsidiary Concord Lifegen Limited

Concord Biotech Limited has incorporated a wholly-owned subsidiary, Concord Lifegen Limited, with an authorized and issued share capital of Rs. 1,00,000. The new entity will focus on marketing, sales, and distribution of pharmaceutical products. Concord Biotech has invested Rs. 1,00,000 for 100% equity ownership, with shares to be allotted within 90 days. The subsidiary aims to execute sales strategies, ensure regulatory compliance, handle logistics, and maintain transparent reporting.

22Jul 25

Concord Biotech Establishes Wholly Owned Subsidiary for Pharmaceutical Marketing and Distribution

Concord Biotech Limited has incorporated a wholly owned subsidiary, Concord Lifegen Limited, on July 21, 2025. The new entity will manage marketing, sales, and distribution of pharmaceutical products. Concord Biotech invested Rs. 1,00,000 for 100% ownership of 10,000 equity shares at Rs. 10 each. The subsidiary aims to enhance commercial efficiency and strengthen Concord Biotech's presence in the biopharmaceutical industry. Concord Lifegen Limited will focus on targeted sales strategies, regulatory compliance, logistics, and customer support across domestic and international markets.

18Jul 25

Concord Biotech's Dholka API Facility Successfully Passes EU GMP Inspection

Concord Biotech Limited announced the successful completion of a European Union Good Manufacturing Practice (EU GMP) inspection at their Active Pharmaceutical Ingredient (API) manufacturing facility in Dholka, Gujarat. The inspection, conducted from July 14 to 18, 2025, validates the company's adherence to European quality and safety standards. This achievement potentially opens up opportunities for Concord Biotech to expand its presence in the European pharmaceutical market and demonstrates its ability to meet international regulatory requirements.

04Jul 25

NCLT Grants Concord Enviro Systems 60-Day Extension for Settlement Talks with Subsidiary

The National Company Law Tribunal (NCLT) has given Concord Biotech a 60-day extension to engage in settlement discussions with one of its units. This development indicates ongoing disputes between the parent company and its subsidiary, with the extension providing an opportunity for out-of-court resolution. The specific timeframe underscores the urgency of the matter, and the outcome of these talks could have significant implications for Concord Biotech's operations and financial standing.

24Jun 25

Concord Biotech's Dholka API Plant Passes U.S. FDA Inspection with Flying Colors

Concord Biotech Limited's Active Pharmaceutical Ingredient (API) manufacturing facility in Dholka, Gujarat, has successfully passed a U.S. Food and Drug Administration (FDA) inspection with no observations. This outcome indicates the facility's compliance with FDA's quality and safety standards, potentially strengthening the company's position in the global pharmaceutical market, especially in the United States. The clean inspection report demonstrates Concord Biotech's commitment to maintaining high-quality standards and regulatory compliance in API manufacturing.

30May 25

Concord Biotech's Q4 Net Profit Soars to ₹1.4 Billion, Announces ₹10.70 Dividend

Concord Biotech's Q4 results show significant growth with net profit reaching ₹1.40 billion, up 44% year-over-year. Revenue increased by 34.4% to ₹4.30 billion. The company's board has recommended a dividend of ₹10.70 per equity share.

29May 25

Concord Biotech Reports Robust Q4 Performance with Surge in Profits and Revenue, Recommends Dividend

Concord Biotech has reported impressive Q4 financial results with significant growth across key metrics. The company's EBITDA increased to ₹1.90 billion from ₹1.34 billion year-over-year, with EBITDA margin expanding to 44.30%. Net profit rose to ₹1.40 billion, up from ₹972.00 million in the previous year. Revenue reached ₹4.30 billion, showing robust growth from ₹3.20 billion last year. The company has also recommended a dividend of ₹10.70 per equity share.

05May 25

Concord Biotech's Dholka Facility Receives Form 483 After USFDA Inspection

Concord Biotech's Dholka facility underwent a USFDA inspection from April 28 to May 2, 2025. The inspection concluded with the issuance of a Form 483 containing four observations. While the specific nature of the observations remains undisclosed, the company is expected to respond with corrective actions to address the FDA's concerns.

02May 25

Concord Biotech's Dholka API Facility Receives FDA Form 483 After Inspection

Concord Biotech Limited's API facility in Dholka, Gujarat, underwent a USFDA inspection from April 28 to May 2, 2025. The inspection concluded with a Form 483 containing four observations, which the company claims are procedural and not related to data integrity. Concord Biotech plans to respond to the USFDA within the required timeframe and is confident in addressing the observations quickly.

09Apr 25

Concord Biotech Secures USFDA Approval for Teriflunomide Tablets, Eyeing $402.00 Million US Market

Concord Biotech Limited has received final USFDA approval to market Teriflunomide Tablets in 7 mg and 14 mg strengths for treating relapsing forms of multiple sclerosis. The US market for this drug is estimated at $402 million, with a global market of $908 million. This approval demonstrates Concord Biotech's capability in developing complex generic drugs and positions the company for expansion in the US pharmaceutical market.

08Apr 25

Concord Biotech Secures FDA Approval for Teriflunomide Tablets, Eyeing $402 Million US Market

Concord Biotech Limited has received final approval from the USFDA to market Teriflunomide tablets in 7 mg and 14 mg strengths for treating relapsing forms of multiple sclerosis. The U.S. market for this drug is valued at approximately $402 million, with a global market of $908 million. This approval marks a significant milestone for the company's expansion into the U.S. pharmaceutical market.

25Mar 25

Concord Biotech Launches Injectable Production at New Valthera Facility

Concord Biotech Limited has successfully commissioned and commenced injectable production at its new Unit-4 manufacturing facility in Valthera on March 25, 2025. The state-of-the-art facility, designed to meet international standards, is equipped with advanced technology for high-quality injectable products. This strategic expansion is expected to enhance the company's manufacturing capabilities and market position in the pharmaceutical sector.

20Feb 25

Concord Biotech Strengthens Global Standing with Successful MFDS Inspection

Concord Biotech Limited successfully completed an inspection by the Ministry of Food and Drug Safety (MFDS) at its Manufacturing Unit I in Dholka, Gujarat. The inspection, conducted from February 18 to February 20, 2025, focused on the company's API facility. This achievement is expected to reinforce Concord Biotech's quality assurance standards, potentially enhance its access to global markets, and strengthen its position in the biotech industry.